Cannabics Pharmaceuticals Announces Positive Results for Pilot Study on Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

MMJ reduces opioid use

Preliminary findings showed +80% of patients had increase in appetite and 60% +10% weight increase ISRAEL & MARYLAND: Cannabics Pharmaceuticals, a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced the results of its pilot study to test the efficacy of Cannabics capsules for the treatment of cancer anorexia-cachexia syndrome (CACS) in advanced Read the full article…